Brief: Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210
02/06/2025 13:33
June 2 (Reuters) - Lyra Therapeutics Inc LYRA.O: LYRA THERAPEUTICS REPORTS POSITIVE RESULTS FROM THE ENLIGHTEN 2 PHASE 3 TRIAL OF LYR-210 ACHIEVING STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN THE TREATMENT OF CHRONIC RHINOSINUSITIS (CRS) LYRA THERAPEUTICS INC - LYR-210 WELL-TOLERATED WITH SAFETY PROFILE SIMILAR TO SHAM CONTROL Source text: ID:nGNX9Jz4zy Further company coverage: LYRA.O ((Reuters.Briefs@thomsonreuters.com;))